In vivo dosimetry in external beam radiotherapy
In vivo dosimetry in external beam radiotherapy
复制标题
DOI：
10.1118/1.4811216
复制
发表时间：
2013-07-01
期刊：
影响因子：
3.8
通讯作者：
Reft, Chester
中科院分区：
文献类型：
--
作者：
Mijnheer, Ben;Beddar, Sam;Reft, Chester
体内剂量测定 (IVD) 在外照射放射治疗 (EBRT) 中用于检测重大错误、评估计划剂量和交付剂量之间的临床相关差异、记录个体患者接受的剂量并满足法律要求。在简要讨论了最常用的IVD系统的主要特点后，总结了EBRT期间IVD的临床经验。在 EBRT 中大规模实施 IVD 需要改进体内剂量测定的传统方面以及开发现有和新兴的非介入技术。这些新技术包括开发电子射野成像设备，用于在 IMRT 和 VMAT 等先进治疗技术期间进行 2D 和 3D 患者剂量测定，以及通过测量辐射引起的放射性核素的衰变在质子和离子放射治疗中使用 IVD。在最终分析中，我们将在这篇 Vision 20/20 论文中表明，除了监管合规性和报销问题之外，体内测量的基本原理是为整个治疗程序提供准确且独立的验证。它将能够识别剂量计算、数据传输、剂量输送、患者设置和患者解剖结构变化中的潜在错误。作者认为，所有具有疗效的治疗都应通过体内剂量测量结合治疗前检查来验证。 (c) 2013 年美国医学物理学家协会。
In vivo dosimetry (IVD) is in use in external beam radiotherapy (EBRT) to detect major errors, to assess clinically relevant differences between planned and delivered dose, to record dose received by individual patients, and to fulfill legal requirements. After discussing briefly the main characteristics of the most commonly applied IVD systems, the clinical experience of IVD during EBRT will be summarized. Advancement of the traditional aspects of in vivo dosimetry as well as the development of currently available and newly emerging noninterventional technologies are required for large-scale implementation of IVD in EBRT. These new technologies include the development of electronic portal imaging devices for 2D and 3D patient dosimetry during advanced treatment techniques, such as IMRT and VMAT, and the use of IVD in proton and ion radiotherapy by measuring the decay of radiation-induced radionuclides. In the final analysis, we will show in this Vision 20/20 paper that in addition to regulatory compliance and reimbursement issues, the rationale for in vivo measurements is to provide an accurate and independent verification of the overall treatment procedure. It will enable the identification of potential errors in dose calculation, data transfer, dose delivery, patient setup, and changes in patient anatomy. It is the authors' opinion that all treatments with curative intent should be verified through in vivo dose measurements in combination with pretreatment checks. (c) 2013 American Association of Physicists in Medicine.